"...this sounds like a fascinating book by Julia Newton-Bishop and Martin Gore who are probably at the forefront for their work in melanoma in this country.
"The book seems readable, and generally the titles for each of the chapters make me want to read it - in fact I want to read this book now!
"In terms of the authors' competence and reputation, as I say, the editors could not be bettered."
Miss Christobel Saunders, Senior Lecturer & Honorary Consultant in Surgery, University College London
"The authors, or should we say editors, are very well known, both in this country and internationally for their interest in melanoma and they are indeed admirably qualified to write such a book. The style seems very practically orientated and in that way is likely to be popular.
"...the list of authors of chapters is excellent in that in each chosen author appears to be an expert in the area he or she has been designated so that apart from the reservation I have stated I would certainly expect the book to do well."
Professor Martin Cook, Professor of Histopathology, Royal Surrey County Hospital
"...this book is a satisfyingly complete review of the controversial issues that need to be addressed by clinicians involved in melanoma. I believe it has certainly achieved the objective I set for it when I picked it up and I have no doubt that it will be seen in all library collections where melanoma patients (and those being screened for melanoma) are being managed..." British Journal of Dermatology, 2002.
Product Description
Reducing the incidence in melanoma incidence by 2005 is an important Health of the Nation objective. The increase in incidence had made it imperative that clinicians managing these patients keep up-to-date with the latest advances, allowing them to provide optimal treatment. As with many other cancers, management is both surgical and medical, and a major focus for new drug development. Inteferon is one such area of activity.
FEATURES covers risk, prevention and screening discusses future therapies, e.g. vaccines covers options for advanced disease BENEFITS practical advice for risk management of interest to clinicians and researchers who and when to treat
See all Editorial Reviews
